H. Mackey

发表

A Randomized Phase II Trial of Vismodegib versus Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients with Previously Untreated Metastatic Colorectal Cancer

J. Berlin, M. Mulcahy, L. Hart, 2012, Clinical Cancer Research.

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer.

Howard Mackey, R. Burger, R. Wenham, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bevacizumab in patients with advanced platinum-resistant ovarian cancer.

R. Burger, R. Wenham, S. Cannistra, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults With Early Alzheimer Disease

Sandra M. Sanabria-Bohórquez, K. Sink, D. Selkoe, 2022, JAMA neurology.

The incidence of metastatic basal cell carcinoma (mBCC) in Denmark, 1997–2010

Lisa I. Wang, J. Hou, N. Basset-Seguin, 2015, European Journal of Dermatology.

ESTIMATING CLINICALLY RELEVANT CHANGE AND DIFFERENCE THRESHOLDS FOR THE CLINICAL DEMENTIA RATING: SUM OF BOXES (CDR-SB) FOR EARLY ALZHEIMER’S DISEASE

P. Delmar, H. Mackey, D. Rofail, 2017, Alzheimer's & Dementia.

Inhibition of the hedgehog pathway in advanced basal-cell carcinoma.

Raoul Tibes, Glen J Weiss, C. Rudin, 2009, The New England journal of medicine.

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Aleksandar Sekulic, Michael R Migden, Axel Hauschild, 2012, The New England journal of medicine.

Safety analysis of a randomized phase II trial of hedgehog pathway inhibitor (HPI) GDC-0449 versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC).

J. Berlin, L. Hart, R. Hermann, 2010 .

The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier coh

L. Schneider, P. Tariot, Ronald G. Thomas, 2018, Alzheimer's & dementia.

Baseline demographic, clinical, and cognitive characteristics of the Alzheimer's Prevention Initiative (API) Autosomal‐Dominant Alzheimer's Disease Colombia Trial

P. Tariot, K. Sink, Yi Su, 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

An industry statistician's perspective on PHC drug development.

J. Fridlyand, R. Yeh, P. Delmar, 2013, Contemporary clinical trials.

Some Notable Properties of the Standard Oncology Phase I Design

Gregory J Hather, Howard Mackey, G. Hather, 2008, Journal of biopharmaceutical statistics.

Power and sample size for random coefficient regression models in randomized experiments with monotone missing data

Ronald Thomas, H. Mackey, Nan Hu, 2021, Biometrical journal. Biometrische Zeitschrift.

Sample size and threshold estimation for clinical trials with predictive biomarkers.

T. Bengtsson, H. Mackey, 2013, Contemporary clinical trials.

A first-in-human, first-in-class, phase (ph) I study of systemic Hedgehog (Hh) pathway antagonist, GDC-0449, in patients (pts) with advanced solid tumors

C. Rudin, M. Borad, P. LoRusso, 2008 .

BASELINE CHARACTERICS FROM A PHASE 3 TRIAL OF CRENEZUMAB IN PRODROMAL TO MILD ALZHEIMER’S DISEASE (CREAD)

K. Sink, R. Doody, P. Fontoura, 2018, Alzheimer's & Dementia.

Abstract LB-138: Efficacy data of GDC-0449, a systemic Hedgehog pathway antagonist, in a first-in-human, first-in-class Phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients

C. Rudin, R. Korn, E. Heath, 2008 .

Abstract B001: Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab

P. Hegde, H. Koeppen, J. Bruey, 2016 .

355 POSTER Updated safety and efficacy data from a first-in-human, first-in-class, phase I study of Hedgehog pathway antagonist, GDC-0449

C. Rudin, P. LoRusso, R. Yauch, 2008 .